scispace - formally typeset
T

Thomas Foltynie

Researcher at UCL Institute of Neurology

Publications -  381
Citations -  26959

Thomas Foltynie is an academic researcher from UCL Institute of Neurology. The author has contributed to research in topics: Deep brain stimulation & Parkinson's disease. The author has an hindex of 80, co-authored 352 publications receiving 21023 citations. Previous affiliations of Thomas Foltynie include University College London & University of Kent.

Papers
More filters
Journal ArticleDOI

Midline Frontal Cortex Low-Frequency Activity Drives Subthalamic Nucleus Oscillations during Conflict

TL;DR: The cortico-subcortical circuit enabling successful choices to be made under conditions of conflict is established and support for the hypothesis that the brain uses frequency-specific channels of communication to convey behaviorally relevant information is provided.
Journal ArticleDOI

BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.

TL;DR: In this article, the influence of a common functional polymorphism of the BDNF gene on the risk of developing dyskinesias in a large cohort of patients with Parkinson's disease, who were independently and variably treated with levodopa and/or other dopaminergic treatments, was investigated.
Journal ArticleDOI

The nucleus basalis of Meynert: A new target for deep brain stimulation in dementia?

TL;DR: The anatomy, intrinsic organization and connectivity of the cholinergic nucleus basalis of Meynert, a basal forebrain structure implicated in cognitive functions including memory, attention, arousal and perception, are described and postulate that deep brain stimulation to this nucleus may be able to improve specific cognitive functions.
Journal ArticleDOI

Prediction of cognition in Parkinson's disease with a clinical-genetic score : a longitudinal analysis of nine cohorts

Ganqiang Liu, +115 more
- 01 Aug 2017 - 
TL;DR: A prediction algorithm for global cognitive impairment (defined as Mini Mental State Examination ≤25) using data from nine cohorts of patients with Parkinson's disease from North America and Europe assessed between 1986 and 2016 is built.